- $266.60m
- $221.94m
- €0.03m
Brief: Inflarx Announces Public Offering Of Ordinary Shares
U.S. STOCKS ON THE MOVE-AMC, Alphabet, Levi Strauss
U.S. STOCKS ON THE MOVE-SeaChange International, AMC, Virgin Orbit
Raymond James raises Inflarx's PT on COVID injection opportunity
InflaRx jumps on FDA's emergency-use authorization for COVID injection
InflaRx gains on FDA's emergency use authorization for COVID injection
InflaRx rises on US FDA's emergency use authorization for COVID injection
InflaRx COVID injection gets US FDA's emergency-use authorization (updated)
InflaRx COVID injection gets US FDA's emergency-use authorization
Brief: Inflarx Receives FDA Emergency Use Authorization For Gohibic
Brief: Inflarx Reports Full Year 2022 Financial And Operating Results
Tesco Bank offers staff 1,250 pound 'cost of living' payment
Brief: InflaRx Provides Update On Planned Phase III Study Design In Pyoderma Gangrenosum With Vilobelimab
Development Agreement And Additional Equity Investment By Staidson For Treatment Of Covid-19
Brief: Inflarx Initiates First-In-Human Study With Small Molecule C5ar Inhibitor Inf904
Brief: Inflarx Reports Third Quarter 2022 Results
Brief: InflaRx Submits Request For Emergency Use Authorization To US FDA
InflaRx surges on plans to seek emergency use authorization for COVID therapy
InflaRx jumps on FDA 'Fast Track' tag for skin ulcer treatment